Medical Advocates
Lopinavir/Ritonavir (Kaletra/Aluvia)
 
Pediatric Indications: Efficacy

LPV/RTV
 LPV/RTV/D4T/3TC 
LPVRTV/3TC
 LPV/RTV/EFV
 LPV/RTV/Multiple Regimens
Salvage Therapy
 LPV/RTV/Rifampin



 

KLS Main Page

Home

Main New/Newsworthy 

Last Update:  August 26, 2017
Posters identified with this icon are in Portable Document Format (PDF) and require the  Adobe Acrobat Reader

LPV/RTV Studies
       
     Journal Papers, Abstracts, and Commentaries
 
 
Brief Report: Lopinavir Hair Concentrations are the Strongest Predictor of Viremia in HIV-infected Asian Children and Adolescents on Second-line Antiretroviral Therapy.
Pintye J, Bacchetti P, Teeraananchai S, et al
J Acquir Immune Defic Syndr. 2017 Aug 18
 Abstract

Sustained Viral Suppression in HIV-Infected Children on Once-Daily Lopinavir/ritonavir in Clinical Practice.
 Gondrie IPE, Bastiaans DET, Fraaij PLA,  et al
Pediatr Infect Dis J. 2017 May 4.
Abstract

FULL-TEXT ARTICLE
Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
Rojas Sánchez P, Prieto L, Jiménez De Ory S, et al
PLoS One. 2017 Mar 28;12(3):e0173168
 Paper

Nevirapine- vs Lopinavir/Ritonavir-based Antiretroviral Therapy in HIV-infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
 Barlow-Mosha L, Angelidou K, Lindsey J,  et al
 Clin Infect Dis. 2016 Jul 20.
 Abstract

Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised ontrolled trial.
 Nagot N, Kankasa C, Tumwine JK, et al
Lancet. 2015 Nov 18.
Abstract


 Virologic Failure Among Children Taking Lopinavir/Ritonavir-containing First-line Antiretroviral Therapy in South Africa.
Meyers T, Sawry S, Wong JY,  et al
 Pediatr Infect Dis J. 2015 Feb;34(2):175-9.
Abstract

Accelerated suppression of primary EBV infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.
Slyker JA, Casper C, Tapia K, et aj
Clin Infect Dis. 2014 Feb 18
Abstract

Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir-ritonavir or nonnucleoside-reverse-transcriptase-inhibitor therapy.
 Ruel T, Kakuru A, Ikilezi G, et al
J Acquir Immune Defic Syndr. 2013 Dec 8
 Abstract

Mortality and Long-Term Virologic Outcomes in Children and Infants Treated with Lopinavir/Ritonavir.
 Estripeaut D, Mosser J, Doherty M,  et al
Pediatr Infect Dis J. 2013 Jun 24.
Abstract

FULL-YEXT PDF ARTICLE
 Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding:
the PROMISE-PEP trial Protocol ANRS 12174.
 Nagot N, Kankasa C, Meda N, et al
BMC Infect Dis. 2012 Oct 6;12(1):246
 Paper

Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
 Violari A, Lindsey JC, Hughes MD,  et al
N Engl J Med. 2012 Jun 21;366(25):2380
 Abstract

Pharmacokinetics and virological efficacy after switch to once-daily lopinavir/r in treatment-
experienced HIV-1 infected children.
 Foissac F, Urien S, Hirt D,  et al
Antimicrob Agents Chemother. 2011 Jul 11
 Abstract

Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of
lopinavir/ritonavir combination antiretroviral therapy.
 Chadwick EG, Yogev R, Alvero CG, et al
AIDS. 2011 Feb
Abstract

Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
 Puthanakit T, van der Lugt J, Bunupuradah T,et al 
 J Antimicrob Chemother. 2009 Sep 2
 Abstract

Early Initiation of Lopinavir/Ritonavir in Infants Less Than 6 Weeks of Age: Pharmacokinetics and
24-Week Safety and Efficacy.
 Chadwick EG, Pinto J, Yogev R,  et al 
Pediatr Infect Dis J. 2009 Feb 9.
 Abstract
 
Long-Term Safety and Effectiveness of Ritonavir, Nelfinavir, and Lopinavir/Ritonavir in Antiretroviral-
Experienced HIV-Infected Children.
 Rudin C, Burri M, Shen Y, et al  
Pediatr Infect Dis J. 2008 Mar 2
 Abstract
 
Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of
age: 24 week results.
 Chadwick EG, Capparelli EV, Yogev R, 
AIDS. 2008 Jan 11;22(2):249-255.
 Abstract

Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following
twice or once daily administration.
Rosso R, Di Biagio A, Dentone C, et al 
J Antimicrob Chemother. 2006 Apr 10;
 Abstract
 

LPV/RTV/D4T/3TC Studies
       

 
48 Week Data

     Journal Papers, Abstracts, and Commentaries
 
  Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in
human immunodeficiency virus-infected children.
 Saez-Llorens X, Violari A, Deetz CO, et al.
Pediatr Infect Dis J 2003 Mar;22(3):216-224
 Abstract

LPV/RTV/3TC
       

    Journal Papers, Abstracts, and Commentaries

  Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
Bouazza N, Foissac F, Fauchet F,  et al
Antivir Ther. 2014 Oct 3.
 Abstract

LPV/RTV/EFV
       

    Journal Papers, Abstracts, and Commentaries

  Increased Dose of Lopinavir/Ritonavir Compensates for Efavirenz-Induced
Drug-Drug Interaction in HIV-1-Infected Children.
Bergshoeff AS, Fraaij PL, Ndagijimana J, et aL 
J Acquir Immune Defic Syndr. 2005 May 1;39(1):63-68.
 Abstract

LPV/RTV/Multiple Drug Studies
       

     Journal Papers, Abstracts, and Commentaries

 
FULL-TEXT ARTICLE
Induction with Lopinavir-Based Treatment Followed by Switch to Nevirapine-Based Regimen versus Non-Nucleoside Reverse Transcriptase Inhibitors-Based Treatment for First Line Antiretroviral Therapy in HIV Infected Children Three Years and Older.
 Alvarez-Uria G, Pakam R, Naik PK, Midde M
 PLoS One. 2014 Sep 18;9(9):e108063.
Paper

Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced
HIV-1-infected children.
 Rudin C, Wolbers M, Nadal D, et al
Arch Dis Child. 2010 Jun;95(6):478-81.
 Abstract

Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of
age: 24 week results.
Chadwick EG, Capparelli EV, Yogev R, et al
AIDS. 2008 Jan 11;22(2):249-55.
 Abstract
 
Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in
pre-treated vertically HIV-infected children.
 Larrú B, Resino S, Bellón JM, et al
J Antimicrob Chemother. 2007 Nov 19;
 Abstract
 
Long-term Follow-up of 414 HIV-Infected Romanian Children and Adolescents
Receiving Lopinavir/Ritonavir-Containing Highly Active Antiretroviral Therapy.
Kline MW, Rugina S, Ilie M, et al 
Pediatrics. 2007 Apr 9;
Abstract

Immunological Changes after Highly Active Antiretroviral Therapy with Lopinavir-
Ritonavir in Heavily Pretreated HIV-Infected Children.
Resino S, Galan I, Perez A, et al  
AIDS Res Hum Retroviruses. 2005 May;21(5):398-4
 Abstract

Salvage Therapy Studies
       

     Journal Papers, Abstracts, and Commentaries

 
Positive virological outcome after lopinavir/ritonavir salvage therapy in protease
inhibitor-experienced HIV-1-infected children: a prospective cohort study.
Resino S, Bellon JM, Ramos JT, et al 
J Antimicrob Chemother. 2004 Oct 7
Abstract

Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily
pretreated HIV-1 vertically infected children.
Galan I, Jimenez JL, Gonzalez-Rivera M, et al
AIDS. 2004 Apr 12;18(2):247-255.
 Abstract
 
 
   

LPV/RTV/Rifampin
       

    Journal Papers, Abstracts, and Commentaries

  Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during
rifampicin-based treatment for tuberculosis.
 McIlleron H, Ren Y, Nuttall J, et al
Antivir Ther. 2011;16(3):417-21
 Abstract

KLS Main Page

Home

Main New/Newsworthy 

Lopinavir/Ritonavir
Pediatric Indications: Efficacy